Please login to the form below

Not currently logged in
Email:
Password:

lasmiditan

This page shows the latest lasmiditan news and features for those working in and with pharma, biotech and healthcare.

Lilly set to head to regulators with CGRP migraine drug

Lilly set to head to regulators with CGRP migraine drug

Lilly recently added to its galcanezumab programme in migraine by buying CoLucid and its lead drug lasmiditan, an oral serotonin 5-HT 1F agonist that is due to be filed for

Latest news

  • Lilly to buy migraine drug developer CoLucid for $960m Lilly to buy migraine drug developer CoLucid for $960m

    Lilly to buy migraine drug developer CoLucid for $960m. Deal revolves around lasmiditan, which the firm out-licensed in 2005. ... Lasmiditan's different mechanism means it could become the first drug that works without vasoconstriction, according to Lilly

  • Migraine drugs' headache Migraine drugs' headache

    CoLucid Pharmaceuticals is developing lasmiditan, which specifically agonises the serotonin 1F receptor.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics